Neurobo Historical Financial Ratios
| NRBO Stock | USD 2.36 0.01 0.43% |
Neurobo Pharmaceuticals is lately reporting on over 89 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Neurobo Pharmaceuticals financial condition quickly.
Neurobo |
About Neurobo Financial Ratios Analysis
Neurobo PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Neurobo Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Neurobo financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Neurobo Pharmaceuticals history.
Neurobo Pharmaceuticals Financial Ratios Chart
Add Fundamental
Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Income Quality
An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.Most ratios from Neurobo Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Neurobo Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.At this time, Neurobo Pharmaceuticals' EV To Free Cash Flow is very stable compared to the past year. As of the 29th of November 2024, Net Debt To EBITDA is likely to grow to 1.47, while Book Value Per Share is likely to drop 3.13.
Neurobo Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
Neurobo Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Neurobo Pharmaceuticals fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 3.72 | 11.82 | 1.93 | 0.0849 | 1.12 | 1.18 | |
| Book Value Per Share | 564.71 | 106.6 | 151.37 | 67.61 | 3.29 | 3.13 | |
| Free Cash Flow Yield | (0.16) | (0.13) | (0.54) | (6.34) | (0.58) | (0.61) | |
| Operating Cash Flow Per Share | (323.38) | (159.3) | (156.94) | (36.41) | (2.13) | (2.24) | |
| Capex To Depreciation | 12.59 | 0.087 | 0.0625 | 8.33 | 7.5 | 7.88 | |
| Pb Ratio | 3.72 | 11.82 | 1.93 | 0.0849 | 1.12 | 1.18 | |
| Free Cash Flow Per Share | (333.21) | (159.36) | (156.97) | (36.41) | (2.14) | (2.25) | |
| Roic | (1.72) | (4.1) | (1.04) | (0.4) | (0.95) | (1.0) | |
| Net Income Per Share | (1.0K) | (437.95) | (157.85) | (19.01) | (2.46) | (2.58) | |
| Cash Per Share | 638.95 | 149.31 | 169.93 | 103.71 | 4.43 | 4.2 | |
| Pocfratio | (6.49) | (7.91) | (1.87) | (0.16) | (1.74) | (1.82) | |
| Capex To Operating Cash Flow | (0.0304) | (3.72E-4) | (1.98E-4) | (0.00463) | (0.004167) | (0.004375) | |
| Pfcf Ratio | (6.3) | (7.91) | (1.87) | (0.16) | (1.73) | (1.82) | |
| Income Quality | 0.33 | 0.36 | 0.99 | 0.84 | 0.87 | 0.57 | |
| Roe | (1.82) | (4.11) | (1.04) | (0.28) | (0.75) | (0.78) | |
| Ev To Operating Cash Flow | (4.53) | (6.98) | (0.79) | 2.69 | 0.32 | 0.34 | |
| Pe Ratio | (2.04) | (2.88) | (1.85) | (0.3) | (1.5) | (1.58) | |
| Return On Tangible Assets | (1.55) | (2.7) | (0.91) | (0.18) | (0.55) | (0.57) | |
| Ev To Free Cash Flow | (4.4) | (6.98) | (0.79) | 2.69 | 0.32 | 0.34 | |
| Earnings Yield | (0.49) | (0.35) | (0.54) | (3.31) | (0.66) | (0.7) | |
| Net Debt To E B I T D A | 0.65 | 0.34 | 1.07 | 2.93 | 1.4 | 1.47 | |
| Current Ratio | 6.78 | 2.89 | 7.69 | 2.85 | 3.78 | 2.86 | |
| Tangible Book Value Per Share | 564.71 | 106.6 | 151.37 | 67.61 | 3.29 | 3.13 | |
| Graham Number | 3.6K | 1.0K | 733.23 | 170.05 | 13.5 | 12.82 | |
| Shareholders Equity Per Share | 564.71 | 106.6 | 151.37 | 67.61 | 3.29 | 3.13 | |
| Debt To Equity | 0.00179 | 0.003332 | 0.001781 | 0.004016 | 0.003614 | 0.003433 | |
| Capex Per Share | 9.83 | 0.0592 | 0.0311 | 0.009864 | 0.0113 | 0.0108 | |
| Graham Net Net | 538.98 | 93.59 | 147.1 | 67.08 | 3.22 | 3.06 | |
| Interest Debt Per Share | 2.02 | 0.93 | 0.27 | 6.81 | 0.0132 | 0.0126 | |
| Debt To Assets | 0.001521 | 0.002188 | 0.001548 | 0.002941 | 0.003382 | 0.003213 | |
| Enterprise Value Over E B I T D A | (1.51) | (2.54) | (0.78) | 2.77 | 0.22 | 0.23 | |
| Short Term Coverage Ratios | (319.95) | (448.5) | (582.08) | (161.18) | (185.36) | (194.62) | |
| Price Earnings Ratio | (2.04) | (2.88) | (1.85) | (0.3) | (1.5) | (1.58) | |
| Price Book Value Ratio | 3.72 | 11.82 | 1.93 | 0.0849 | 1.12 | 1.18 | |
| Price Earnings To Growth Ratio | (0.003936) | 0.05 | 0.029 | 0.003433 | 0.0173 | 0.0181 | |
| Price To Operating Cash Flows Ratio | (6.49) | (7.91) | (1.87) | (0.16) | (1.74) | (1.82) |
Pair Trading with Neurobo Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurobo Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurobo Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Neurobo Stock
| 0.87 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.81 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.76 | ESPR | Esperion Therapeutics | PairCorr |
| 0.75 | GILD | Gilead Sciences | PairCorr |
| 0.74 | BHC | Bausch Health Companies | PairCorr |
The ability to find closely correlated positions to Neurobo Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurobo Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurobo Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurobo Pharmaceuticals to buy it.
The correlation of Neurobo Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurobo Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurobo Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurobo Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobo Pharmaceuticals. If investors know Neurobo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.29) | Return On Assets (0.74) | Return On Equity (1.61) |
The market value of Neurobo Pharmaceuticals is measured differently than its book value, which is the value of Neurobo that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Neurobo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Neurobo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurobo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.